Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost

Prostaglandins and Other Lipid Mediators

Volumn 93, Issue 1-2, 2010, Pages 20-24

  Castagnino, Paola ^a   Kothapalli, Devashish ^a   Hawthorne, Elizabeth A ^a   Xu, Tina ^a   Assoian, Richard K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Endothelial cells; P27kip1 vascular injury; PGI2; Prostacyclin; Rapamycin; Smooth muscle cells

Indexed keywords

CICAPROST; CYCLIN DEPENDENT KINASE INHIBITOR 1B; RAPAMYCIN;

ANIMAL CELL; ARTICLE; BLOOD VESSEL INJURY; CELL CYCLE; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MITOGENESIS; MOUSE; NONHUMAN; PROTEIN DETERMINATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EPOPROSTENOL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MITOSIS; MUSCLE, SMOOTH, VASCULAR; SIROLIMUS;

EID: 77955419868     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.04.004     Document Type: Article

References (25)

1. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004, 364:1519-1521.
2. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006, 48:2584-2591.
3. Yang Z., Simari R.D., Tanner F., Stephan D., Nabel G.J., Nabel E.G. Gene transfer approaches to the regulation of vascular cell proliferation. Semin Interv Cardiol 1996, 1:181-184.
4. Suzuki J., Isobe M., Morishita R., et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997, 3:900-903.
5. MacLellan W.R., Majesky M.W. Cell cycle regulators in vascular disease. Circulation 1997, 96:1717-1719.
6. Chang M.W., Barr E., Seltzer J., et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995, 267:518-522.
7. Marks A.R. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 2003, 349:1307-1309.
8. Marx S.O., Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001, 104:852-855.
9. Woods T.C., Marks A.R. Drug-eluting stents. Annu Rev Med 2004, 55:169-178.
10. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1 phase progression. Genes Dev 1999, 13:1501-1512.
11. Matter C.M., Rozenberg I., Jaschko A., et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2006, 48:286-292.
12. Kothapalli D., Stewart S.A., Smyth E.M., Azonobi I., Pure E., Assoian R.K. Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol Pharmacol 2003, 64:249-258.
13. Stewart S.A., Kothapalli D., Yung Y., Assoian R.K. Antimitogenesis linked to regulation of Skp2 gene expression. J Biol Chem 2004, 279:29109-29113.
14. Fetalvero K.M., Martin K.A., Hwa J. Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat 2007, 82:109-118.
15. Cheng Y., Austin S.C., Rocca B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539-541.
16. Coleman R.A., Grix S.P., Head S.A., Louttit J.B., Mallett A., Sheldrick R.L. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 1994, 47:151-168.
17. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193-1226.
18. Ii M., Hoshiga M., Fukui R., et al. Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1). Cardiovasc Res 2001, 52:500-508.
19. Klein E.A., Yung Y., Castagnino P., Kothapalli D., Assoian R.K. Cell adhesion, cellular tension, and cell cycle control. Methods Enzymol 2007, 426:155-175.
20. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10:307-318.
21. Luo Y., Marx S.O., Kiyokawa H., Koff A., Massague J., Marks A.R. Rapamycin resistance tied to defective regulation of p27Kip1. Mol Cell Biol 1996, 16:6744-6751.
22. Imanishi T., Kobayashi K., Kuki S., Takahashi C., Akasaka T. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 2006, 189:288-296.
23. Bundey R.A., Insel P.A. Adenylyl cyclase 6 overexpression decreases the permeability of endothelial monolayers via preferential enhancement of prostacyclin receptor function. Mol Pharmacol 2006, 70:1700-1707.
24. Shirotani M., Yui Y., Hattori R., Kawai C. U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins 1991, 41:97-110.
25. Jaschke B., Michaelis C., Milz S., et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 2005, 68:483-492.